questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Cytokines
Interleukines
Interleukine-9
Interleukine-9 : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Interleukine-9 : Questions médicales les plus fréquentes",
"headline": "Interleukine-9 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Interleukine-9 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-04",
"dateModified": "2025-03-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Interleukine-9"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Interleukines",
"url": "https://questionsmedicales.fr/mesh/D007378",
"about": {
"@type": "MedicalCondition",
"name": "Interleukines",
"code": {
"@type": "MedicalCode",
"code": "D007378",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.465"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Interleukine-9",
"alternateName": "Interleukin-9",
"code": {
"@type": "MedicalCode",
"code": "D016906",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sushmita Chakraborty",
"url": "https://questionsmedicales.fr/author/Sushmita%20Chakraborty",
"affiliation": {
"@type": "Organization",
"name": "Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi 110029, India."
}
},
{
"@type": "Person",
"name": "Dipendra Kumar Mitra",
"url": "https://questionsmedicales.fr/author/Dipendra%20Kumar%20Mitra",
"affiliation": {
"@type": "Organization",
"name": "Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi 110029, India."
}
},
{
"@type": "Person",
"name": "Mattia Matasci",
"url": "https://questionsmedicales.fr/author/Mattia%20Matasci",
"affiliation": {
"@type": "Organization",
"name": "Philochem AG, CH-8112 Otelfingen, Switzerland."
}
},
{
"@type": "Person",
"name": "Dario Neri",
"url": "https://questionsmedicales.fr/author/Dario%20Neri",
"affiliation": {
"@type": "Organization",
"name": "Philochem AG, CH-8112 Otelfingen, Switzerland."
}
},
{
"@type": "Person",
"name": "Katharina F Kubatzky",
"url": "https://questionsmedicales.fr/author/Katharina%20F%20Kubatzky",
"affiliation": {
"@type": "Organization",
"name": "Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University, Heidelberg, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Current epidemiology of cholangiocarcinoma in Western countries.",
"datePublished": "2022-08-14",
"url": "https://questionsmedicales.fr/article/35977611",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jhep.2022.07.022"
}
},
{
"@type": "ScholarlyArticle",
"name": "Nivolumab for treating patients with occupational cholangiocarcinoma.",
"datePublished": "2022-08-08",
"url": "https://questionsmedicales.fr/article/35793385",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jhbp.1215"
}
},
{
"@type": "ScholarlyArticle",
"name": "Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.",
"datePublished": "2022-09-20",
"url": "https://questionsmedicales.fr/article/36123506",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12072-022-10419-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Characteristics and clinical outcomes in young-onset cholangiocarcinoma.",
"datePublished": "2023-05-22",
"url": "https://questionsmedicales.fr/article/37212509",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cam4.6063"
}
},
{
"@type": "ScholarlyArticle",
"name": "Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.",
"datePublished": "2023-03-01",
"url": "https://questionsmedicales.fr/article/36936931",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1142690"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Cytokines",
"item": "https://questionsmedicales.fr/mesh/D016207"
},
{
"@type": "ListItem",
"position": 5,
"name": "Interleukines",
"item": "https://questionsmedicales.fr/mesh/D007378"
},
{
"@type": "ListItem",
"position": 6,
"name": "Interleukine-9",
"item": "https://questionsmedicales.fr/mesh/D016906"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Interleukine-9 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Interleukine-9",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Interleukine-9",
"description": "Comment mesurer l'interleukine-9 ?\nQuels tests sont utilisés pour le diagnostic ?\nL'IL-9 est-elle liée à des maladies spécifiques ?\nQuels biomarqueurs sont associés à l'IL-9 ?\nL'IL-9 peut-elle être un indicateur de gravité ?",
"url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Cholangiocarcinoma&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Interleukine-9",
"description": "Quels symptômes sont liés à l'IL-9 ?\nL'IL-9 provoque-t-elle des symptômes respiratoires ?\nY a-t-il des symptômes cutanés associés ?\nL'IL-9 est-elle liée à des symptômes gastro-intestinaux ?\nQuels signes cliniques sont observés ?",
"url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Cholangiocarcinoma&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Interleukine-9",
"description": "Comment prévenir les maladies liées à l'IL-9 ?\nY a-t-il des vaccins pour l'IL-9 ?\nL'éducation des patients est-elle importante ?\nLes changements alimentaires peuvent-ils aider ?\nLe contrôle de l'environnement est-il crucial ?",
"url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Cholangiocarcinoma&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Interleukine-9",
"description": "Comment traiter les niveaux élevés d'IL-9 ?\nY a-t-il des thérapies ciblées pour l'IL-9 ?\nLes corticostéroïdes affectent-ils l'IL-9 ?\nQuels médicaments sont utilisés pour l'asthme lié à l'IL-9 ?\nL'immunothérapie aide-t-elle avec l'IL-9 ?",
"url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Cholangiocarcinoma&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Interleukine-9",
"description": "Quelles complications peuvent survenir avec l'IL-9 ?\nL'IL-9 peut-elle aggraver d'autres maladies ?\nY a-t-il des risques de surinfection ?\nDes complications pulmonaires sont-elles possibles ?\nL'IL-9 est-elle liée à des troubles cardiovasculaires ?",
"url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Cholangiocarcinoma&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Interleukine-9",
"description": "Quels sont les facteurs de risque pour l'IL-9 ?\nL'exposition à la pollution augmente-t-elle le risque ?\nLe tabagisme influence-t-il l'IL-9 ?\nLes infections respiratoires sont-elles un facteur ?\nLe stress a-t-il un impact sur l'IL-9 ?",
"url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Cholangiocarcinoma&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment mesurer l'interleukine-9 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IL-9 peut être mesurée par des tests ELISA dans le sérum ou les fluides biologiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses de cytokines sont utilisés pour évaluer l'IL-9."
}
},
{
"@type": "Question",
"name": "L'IL-9 est-elle liée à des maladies spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-9 est associée à des maladies comme l'asthme et certaines allergies."
}
},
{
"@type": "Question",
"name": "Quels biomarqueurs sont associés à l'IL-9 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IL-9 est souvent mesurée avec d'autres cytokines comme l'IL-4 et l'IL-5."
}
},
{
"@type": "Question",
"name": "L'IL-9 peut-elle être un indicateur de gravité ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés d'IL-9 peuvent indiquer une inflammation sévère."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à l'IL-9 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des réactions allergiques, de l'asthme et des inflammations."
}
},
{
"@type": "Question",
"name": "L'IL-9 provoque-t-elle des symptômes respiratoires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-9 est impliquée dans l'hyperréactivité bronchique et l'asthme."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent survenir dans des conditions allergiques liées à l'IL-9."
}
},
{
"@type": "Question",
"name": "L'IL-9 est-elle liée à des symptômes gastro-intestinaux ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-9 peut être impliquée dans des troubles gastro-intestinaux allergiques."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des difficultés respiratoires, des éruptions cutanées et des démangeaisons."
}
},
{
"@type": "Question",
"name": "Comment prévenir les maladies liées à l'IL-9 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les allergènes et adopter un mode de vie sain peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour l'IL-9 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour cibler l'IL-9."
}
},
{
"@type": "Question",
"name": "L'éducation des patients est-elle importante ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer les patients sur les déclencheurs allergiques est essentiel pour la prévention."
}
},
{
"@type": "Question",
"name": "Les changements alimentaires peuvent-ils aider ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut aider à réduire l'inflammation et les symptômes."
}
},
{
"@type": "Question",
"name": "Le contrôle de l'environnement est-il crucial ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, réduire l'exposition aux allergènes environnementaux est essentiel pour la prévention."
}
},
{
"@type": "Question",
"name": "Comment traiter les niveaux élevés d'IL-9 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements anti-inflammatoires et des antihistaminiques peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies ciblées pour l'IL-9 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anticorps monoclonaux ciblant l'IL-9 sont en développement pour traiter l'asthme."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes affectent-ils l'IL-9 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent réduire les niveaux d'IL-9 et l'inflammation associée."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour l'asthme lié à l'IL-9 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les bronchodilatateurs et les corticostéroïdes sont couramment prescrits."
}
},
{
"@type": "Question",
"name": "L'immunothérapie aide-t-elle avec l'IL-9 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'immunothérapie peut aider à moduler la réponse immunitaire liée à l'IL-9."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'IL-9 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des exacerbations d'asthme et des réactions allergiques sévères."
}
},
{
"@type": "Question",
"name": "L'IL-9 peut-elle aggraver d'autres maladies ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-9 peut exacerber des maladies auto-immunes et inflammatoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de surinfection ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients avec des niveaux élevés d'IL-9 peuvent être à risque de surinfections."
}
},
{
"@type": "Question",
"name": "Des complications pulmonaires sont-elles possibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IL-9 peut contribuer à des complications pulmonaires comme la fibrose."
}
},
{
"@type": "Question",
"name": "L'IL-9 est-elle liée à des troubles cardiovasculaires ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien entre l'IL-9 et des troubles cardiovasculaires, mais c'est encore à étudier."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'IL-9 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux d'allergies et d'asthme augmentent le risque d'IL-9 élevée."
}
},
{
"@type": "Question",
"name": "L'exposition à la pollution augmente-t-elle le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la pollution de l'air est un facteur de risque connu pour les maladies liées à l'IL-9."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il l'IL-9 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter les niveaux d'IL-9 et aggraver les symptômes respiratoires."
}
},
{
"@type": "Question",
"name": "Les infections respiratoires sont-elles un facteur ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections respiratoires peuvent déclencher une réponse immunitaire impliquant l'IL-9."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur l'IL-9 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut exacerber les symptômes et augmenter les niveaux d'IL-9."
}
}
]
}
]
}
Cholangiocarcinomas are cancers arising from bile ducts, either found within the liver (intrahepatic) or outside the liver (extrahepatic). In Western countries, deaths due to intrahepatic cancers are ...
Tanaka et al. previously reported a case in which nivolumab for recurrent occupational cholangiocarcinoma resulted in complete response persisting for 26 months after discontinuation. Afterward, in th...
Integration of HBV DNA into the human genome could progressively contribute to hepatocarcinogenesis. Both intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular-cholangiocarcinoma (CHC) are...
41 patients with ICC and 20 patients with CHC were recruited in the study. We conducted HIVID analysis on these 61 samples to identify HBV integration sites in both the tumor tissues and adjacent non-...
We detected 493 HBV integration sites in ICC patients, of which 417 were from tumor samples and 76 were from non-tumor samples. And 246 HBV integration sites were detected in CHC patients, of which 15...
Comparative analysis demonstrates numerous newly discovered mutational events in ICC and CHC resulting from HBV insertions in the host genome. Our study provides an in-depth biological and clinical in...
While the incidence of cholangiocarcinoma is rising, little is known about young-onset disease. We compared clinical characteristics and outcomes between patients with young-onset cholangiocarcinoma, ...
We used the National Cancer Database to identify patients with young-onset cholangiocarcinoma (n = 2520) and typical-onset cholangiocarcinoma (n = 23,826). We compared the frequency of demographic and...
When compared to patients with typical-onset disease (median age 68 years), patients with young-onset cholangiocarcinoma (median age 44 years) were more likely to be non-White (35.0% vs. 27.4%, p < 0....
Patients with young-onset cholangiocarcinoma may represent a demographically and clinically distinct group from those with more typical-onset disease....
Cholangiocarcinoma (CCA) is a rare and aggressive type of malignant tumor. In the past few years, there has been an increase in the incidence of CCA. Surgery is the only effective treatment but is onl...
It is difficult to directly obtain pathological diagnosis of perihilar cholangiocarcinoma (pCCA). Analysis of bile in the pCCA microenvironment, based on metabolomics and statistical methods, can help...
Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA ...
In addition to conditioning measures in liver surgery, perioperative anti-tumor therapy is becoming increasingly more important in cholangiocarcinoma (CCA)....
Systematic literature review on the status of multimodal and in particular neoadjuvant therapy for CCA....
Literature overview of the current scientific original and review articles....
Resection and rarely also liver transplantation are still the only curative treatment approaches for CCA in the non-distant metastatic stage; however, long-term results, e.g. in node positive tumors, ...
There is a high potential for the use of multimodal therapy in CCA, which could further increase in the near future as a result of new therapeutic agents. Due to the lack of evidence clear recommendat...
Hepatocellular carcinoma and intrahepatic cholangiocarcinoma are the two most common primary malignant tumors of the liver. The similarities and variations in imaging characteristics that may aid in d...
Cholangiocarcinoma (CCA) is an invasive cancer accounting for <1% of all cancers and 10-15% of primary liver cancers. Intrahepatic CCA (iCCA) is associated with poor survival rates and high post-surgi...